OPTIMIZING LENTIVIRAL VECTOR PRODUCTION FOR CELL THERAPIES: ADVANCING MANUFACTURING STRATEGIES AT OMNIABIO

被引：0

作者：

Al Asafen, H. ^{[2
]}

Sudarsan, A. K. ^{[1
]}

Mcleod, A. ^{[2
]}

Kawka, K. ^{[2
]}

Maystrenko, A. ^{[2
]}

Sirskyj, D. ^{[2
]}

Bagheri, M. ^{[3
]}

Attignon, E. ^{[3
]}

Chettiar, D. ^{[1
]}

Beaudette, P. ^{[1
]}

Razvi, A. ^{[2
]}

Patel, N. ^{[1
]}

McNally, K. ^{[4
]}

Gacerez, A. ^{[4
]}

Fardy, M. ^{[4
]}

机构：

[1] Ctr Commercializat Regenerat Med, Toronto, ON, Canada

[2] Cytiva US, Marlborough, MA USA

[3] OmniaBio, Toronto, ON, Canada

[4] Chimera Bioengn, San Francisco, CA USA

来源：

CYTOTHERAPY | 2024年 / 26卷 / 06期

关键词：

lentivirus; bioreactor; process development;

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

1143

引用

页码：E29 / E30

页数：2

共 50 条

[21] Novel Constitutive Producer Cell Line & GMP Compatible Dowstream Process for Lentiviral Vector Manufacturing
Tomas, Helio A.
Oliveiras, Ana S.
Rodrigues, Ana F.
Faria, Tiago
Carrondo, Manuel J. T.
Alves, Paula M.
Peixoto, Cristina
Coroadinha, Ana S.
MOLECULAR THERAPY, 2018, 26 (05) : 152 - 152
[22] Lentiviral/retroviral vector manufacturing production using disposable fixed-bed bioreactors iCELLis® system
Neri, M.
Bellintani, F.
Cota, M.
Crippa, L.
Brunati, M.
Piovani, B.
Allievi, L.
Testasecca, A.
Pedregal, A.
Gatti, A.
Rossetti, F.
Vallanti, G.
HUMAN GENE THERAPY, 2017, 28 (12) : A117 - A118
[23] Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing
Luostarinen, Annu
Kailaanmaki, Anssi
Turkki, Vesa
Koylijarvi, Marjut
Kayhty, Piia
Leinonen, Hanna
Albers-Skirdenko, Vita
Lipponen, Eevi
Yla-Herttuala, Seppo
Kaartinen, Tanja
Lesch, Hanna P.
Kekarainen, Tuija
CYTOTHERAPY, 2024, 26 (09) : 1084 - 1094
[24] LentiPro26: novel stable cell lines for constitutive lentiviral vector production
Tomas, H. A.
Rodrigues, A. F.
Carrondo, M. J. T.
Coroadinha, A. S.
SCIENTIFIC REPORTS, 2018, 8
[25] LentiPro26: novel stable cell lines for constitutive lentiviral vector production
H. A. Tomás
A. F. Rodrigues
M. J. T. Carrondo
A. S. Coroadinha
Scientific Reports, 8
[26] Evaluation of Residual Host Cell DNA Clearance and Sizing During Production of a Lentiviral Vector
Youngman, Elaine M.
Miranda, Meiling
Edwards, Shanice
O'Malley, Thomas M.
Richardson, James C.
Culp, Tim C.
Johnson, Philip R.
MOLECULAR THERAPY, 2024, 32 (04) : 647 - 647
[27] Lentiviral Vector Manufacturing: Success in Scaling up to Various Batch Sizes Using Univercells Technologies' Production System
Cristovao, Filipe
Carlos Munoz, Juan
Jose Davila, Maria
Chatel, Alex
Mesado, Gonzalo
MOLECULAR THERAPY, 2021, 29 (04) : 407 - 407
[28] Optimizing cryopreservation strategies for scalable cell therapies: A comprehensive review with insights from iPSC-derived therapies
Dobruskin, Michael
Toner, Geoffrey
Kander, Ronald
BIOTECHNOLOGY PROGRESS, 2024,
[29] Host Cell Restriction Factors Blocking Efficient Vector Transduction: Challenges in Lentiviral and Adeno-Associated Vector Based Gene Therapies
Coroadinha, Ana Sofia
CELLS, 2023, 12 (05)
[30] Translational Studies toward Optimizing In Vivo Bone Marrow Stem Cell Gene Transfer Using Lentiviral Vector
Worsham, D. Nicole
Wang, Daren
von Kalle, Christof
Williams, David A.
Pan, Dao
MOLECULAR THERAPY, 2006, 13 : S40 - S40

← 1 2 3 4 5 →